Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $138.21 USD
Change Today -0.02 / -0.01%
Volume 481.0K
SIAL On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

sigma-aldrich (SIAL) Snapshot

Open
$138.15
Previous Close
$138.23
Day High
$138.35
Day Low
$138.10
52 Week High
02/23/15 - $138.83
52 Week Low
04/15/14 - $91.61
Market Cap
16.5B
Average Volume 10 Days
887.7K
EPS TTM
$4.36
Shares Outstanding
119.5M
EX-Date
02/25/15
P/E TM
31.7x
Dividend
$0.92
Dividend Yield
0.67%
Current Stock Chart for SIGMA-ALDRICH (SIAL)

sigma-aldrich (SIAL) Related Businessweek News

No Related Businessweek News Found

sigma-aldrich (SIAL) Details

Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide. The company provides chemical products, reagents, and kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and diagnosis of disease; and as key components in pharmaceutical, diagnostics, and high technology manufacturing. It offers media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing. The company sells its products to pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies, non-profit organizations, governmental institutions, diagnostic, chemical and electronics companies, and hospitals. Sigma-Aldrich Corporation was founded in 1951 and is based in St. Louis, Missouri.

9,300 Employees
Last Reported Date: 02/12/15
Founded in 1951

sigma-aldrich (SIAL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $485.4K
Executive Vice President and President of App...
Total Annual Compensation: $455.7K
Executive Vice President and President of SAF...
Total Annual Compensation: $404.2K
Executive Vice President and President of Res...
Total Annual Compensation: $369.2K
Compensation as of Fiscal Year 2014.

sigma-aldrich (SIAL) Key Developments

Sigma-Aldrich Corporation Announces Exclusive Distribution Agreement with Roche

Sigma-Aldrich Corporation announced it signed an exclusive global distribution agreement with Roche. The agreement pairs Roche's high-quality Biochemical Reagents product portfolio with the eCommerce and supply chain capabilities of Sigma-Aldrich. Under the agreement, Sigma-Aldrich will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute the Roche Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications.

SAFC Commercial Enters into Sales and Service Contract with Beigene

Sigma-Aldrich Corporation has announced that SAFC Commercial has entered into commercial sales and service contract with BeiGene.

BeiGene Selects SAFC Commercial's CHOZN® Platform for Commercial Drug Development

Sigma-Aldrich Corporation announced that SAFC Commercial, its custom manufacturing services business unit, entered a commercial sales and service contract with BeiGene. BeiGene purchased SAFC's off-the-shelf, turnkey CHOZN cell line production platform and cell line engineering services to support discovery and commercial development of BeiGene's targeted oncology drug. The CHOZN Platform supports efficient innovation and the high quality therapeutics. It offers a turnkey solution that is unmatched in the industry. Users simply identify and clone the genes for their therapeutic protein of interest into the CHOZN expression vector, and then employ the traditional cell line development strategies of transfection, selection and cloning. The CHOZN Platform is designed to deliver a robust producing clone - ready for manufacturing.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIAL:US $138.21 USD -0.02

SIAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,415 INR -30.30
International Flavors & Fragrances Inc $117.18 USD +0.48
Symrise AG €57.90 EUR -0.349
UCB SA €68.49 EUR +0.87
Waters Corp $124.11 USD +2.26
View Industry Companies
 

Industry Analysis

SIAL

Industry Average

Valuation SIAL Industry Range
Price/Earnings 33.2x
Price/Sales 5.9x
Price/Book 5.3x
Price/Cash Flow 33.0x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGMA-ALDRICH, please visit www.sigmaaldrich.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.